Developer docs
API playgroundTry for free, no card

Search company profiles

Novitium Pharma

Full company profile

uuid000a4et

Namestring
Novitium Pharma
Legal namestring
Novitium Pharma LLC
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Novitium Pharma is a US-based specialty pharmaceutical company founded in 2016 and headquartered in East Windsor, New Jersey, focused on the development, manufacturing, and distribution of niche generic pharmaceutical products. The company operates a state-of-the-art manufacturing facility at 70 Lake Drive, staffed by pharmaceutical scientists, engineers, and executives with over 50 years of combined experience. Its commercial portfolio spans multiple dosage forms and therapeutic categories, including Famotidine for Oral Suspension (generic Pepcid®), Fluphenazine Hydrochloride Tablets (generic Prolixin®), Sildenafil for Oral Suspension (generic Revatio®), and Thiothixene Capsules (generic Navane®), with all products manufactured domestically in the United States.

The company's go-to-market is B2B sales-led, targeting pharmacists as primary customers who in turn dispense to patients, with a horizontal segmentation approach across therapeutic categories rather than vertical specialization. Novitium has positioned itself in less competitive segments of the generics market — including antipsychotics, acid reduction, and pulmonary arterial hypertension — and has been identified as a key participant in the global Carglumic Acid market alongside Recordati Rare Diseases and Eton Pharmaceuticals. The value proposition emphasizes affordable prescription medicines, science-driven formulation, US-based quality control, and responsive execution in dynamic supply markets.

In 2021, Novitium was acquired by ANI Pharmaceuticals (NASDAQ: ANIP) and now operates as a wholly-owned subsidiary integrated into ANI's generics and CDMO operations. As a result, Novitium's product quality complaints and adverse event reporting channels have been consolidated under ANI (drugsafety@anipharmaceuticals.com and complaints@anipharmaceuticals.com), and the company's website explicitly identifies it as part of ANI Pharmaceuticals. The founders — Muthusamy Shanmugam, Chad Gassert (co-founder and CEO), and Vijay Thorappadi — continue to be associated with the business. No standalone revenue, funding rounds, patents, or AI/technology capabilities are disclosed in the available data.

Short descriptiontext

Novitium Pharma is a US-based niche generic pharmaceutical company founded in 2016, developing, manufacturing, and distributing affordable generic medications in oral suspension, tablet, and capsule forms. Acquired by ANI Pharmaceuticals in 2021, it serves pharmacists and patients across diverse therapeutic categories from its East Windsor, NJ facility.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWindsor, United States
HQ citystring
Windsor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, niche generic medications, oral suspension formulations, prescription drug manufacturing, US-based pharmaceutical manufacturing
Industry2 codes
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Products
TypeOne Time License
Description

Novitium generates revenue through the development, manufacturing, and distribution of niche generic pharmaceutical products. The company sells generic versions of brand medications across various dosage forms and therapeutic categories.

novitiumpharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Novitium Pharma develops, manufactures, and distributes niche generic pharmaceutical products in dosage forms including oral suspensions, tablets, and capsules across various therapeutic categories. The company's products are manufactured at a state-of-the-art facility in East Windsor, New Jersey, and address formulations with limited competition in the generics market.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Novitium Pharma is a U.S.-based pharmaceutical company specializing in development, manufacturing, and distribution of niche generic products. Founded in 2016, the company offers a portfolio of high-quality generic medications including oral suspensions (Famotidine, Sildenafil), tablets (Fluphenazine Hydrochloride), and capsules (Thiothixene). Novitium Pharma operates as part of ANI Pharmaceuticals following its acquisition and serves pharmacists and patients by providing affordable prescription options. The company's products span diverse therapeutic categories and dosage forms, all proudly manufactured in the USA at their state-of-the-art facility in East Windsor, New Jersey.

Product and service4 records
1Famotidine for Oral Suspension, USP
CategoryGeneric Pharmaceuticals
Description

Generic oral suspension formulation of Famotidine manufactured and distributed by Novitium Pharma.

2Fluphenazine Hydrochloride Tablets, USP
CategoryGeneric Pharmaceuticals
Description

Generic tablet formulation of Fluphenazine Hydrochloride manufactured and distributed by Novitium Pharma.

3Sildenafil for Oral Suspension
CategoryGeneric Pharmaceuticals
Description

Generic oral suspension formulation of Sildenafil manufactured and distributed by Novitium Pharma.

4Thiothixene Capsules, USP
CategoryGeneric Pharmaceuticals
Description

Generic capsule formulation of Thiothixene manufactured and distributed by Novitium Pharma.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Novitium Pharma was acquired by ANI Pharmaceuticals in 2021. This acquisition significantly enhanced ANI's R&D capabilities and scale of generics and CDMO businesses. Novitium now operates as part of ANI Pharmaceuticals, with its website indicating Novitium is now part of ANI Pharmaceuticals.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Amneal Pharmaceuticals is a major US-based generic pharmaceutical manufacturer with a similarly diverse portfolio spanning multiple dosage forms and therapeutic categories. Both serve pharmacy channels with affordable generics and share manufacturing footprint overlap.

TypeDirect peer
Description

Recordati Rare Diseases is identified alongside Novitium as a key Carglumic Acid competitor and operates in rare-disease and specialty pharmaceuticals. Direct overlap exists in niche/rare generic and specialty therapeutics.

TypeBroad incumbent
Description

ANI Pharmaceuticals (NASDAQ: ANIP) is the publicly-traded parent company that acquired Novitium in 2021. It operates a broader generics, specialty, and CDMO portfolio and shares overlap with Novitium across generic pharmaceuticals and contract manufacturing, making it the most directly comparable broad incumbent.

TypeDirect peer
Description

Lannett Company is a US-based generic pharmaceutical manufacturer focused on oral solid, liquid, and topical dosage forms distributed through pharmacy channels. It directly overlaps with Novitium's generic portfolio approach and distribution model.

TypeDirect peer
Description

Upsher-Smith Laboratories is a US-based generic and specialty pharmaceutical manufacturer producing tablets, capsules, and oral liquids. Its niche-focused generic strategy and US manufacturing footprint closely mirror Novitium's operating model.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with extensive operations in the US across tablets, capsules, and oral suspensions. It represents the broad incumbent competitive benchmark against which niche generic players like Novitium compete.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Sandoz is a global leader in generics and biosimilars with substantial US presence across all major dosage forms. Relevant broad incumbent for benchmarking Novitium's positioning in the US generic pharmaceutical market.

TypeBroad incumbent
Description

Endo International is a broad specialty and generic pharmaceutical manufacturer with significant US generic operations across multiple therapeutic categories. Comparable to Novitium as a larger incumbent in the US generics market.

9Woodward Pharma Services
TypeEmerging player
Description

Woodward Pharma Services is a smaller US-based specialty generic manufacturer focused on niche therapeutic categories with limited competition. It shares Novitium's niche-targeting strategy and sub-scale emerging-player profile.

TypeDirect peer
Description

Eton Pharmaceuticals is a niche specialty pharmaceutical company explicitly identified alongside Novitium as a key player in the Carglumic Acid market. Both companies target underserved therapeutic niches with small, focused product portfolios and similar business models.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novitium Pharma

Generic Pharmaceuticalsnovitiumpharma.com

Novitium Pharma is a US-based niche generic pharmaceutical company founded in 2016, developing, manufacturing, and distributing affordable generic medications in oral suspension, tablet, and capsule forms. Acquired by ANI Pharmaceuticals in 2021, it serves pharmacists and patients across diverse therapeutic categories from its East Windsor, NJ facility.

What Novitium Pharma does

Novitium Pharma is a US-based specialty pharmaceutical company founded in 2016 and headquartered in East Windsor, New Jersey, focused on the development, manufacturing, and distribution of niche generic pharmaceutical products. The company operates a state-of-the-art manufacturing facility at 70 Lake Drive, staffed by pharmaceutical scientists, engineers, and executives with over 50 years of combined experience. Its commercial portfolio spans multiple dosage forms and therapeutic categories, including Famotidine for Oral Suspension (generic Pepcid®), Fluphenazine Hydrochloride Tablets (generic Prolixin®), Sildenafil for Oral Suspension (generic Revatio®), and Thiothixene Capsules (generic Navane®), with all products manufactured domestically in the United States.

The company's go-to-market is B2B sales-led, targeting pharmacists as primary customers who in turn dispense to patients, with a horizontal segmentation approach across therapeutic categories rather than vertical specialization. Novitium has positioned itself in less competitive segments of the generics market — including antipsychotics, acid reduction, and pulmonary arterial hypertension — and has been identified as a key participant in the global Carglumic Acid market alongside Recordati Rare Diseases and Eton Pharmaceuticals. The value proposition emphasizes affordable prescription medicines, science-driven formulation, US-based quality control, and responsive execution in dynamic supply markets.

In 2021, Novitium was acquired by ANI Pharmaceuticals (NASDAQ: ANIP) and now operates as a wholly-owned subsidiary integrated into ANI's generics and CDMO operations. As a result, Novitium's product quality complaints and adverse event reporting channels have been consolidated under ANI (drugsafety@anipharmaceuticals.com and complaints@anipharmaceuticals.com), and the company's website explicitly identifies it as part of ANI Pharmaceuticals. The founders — Muthusamy Shanmugam, Chad Gassert (co-founder and CEO), and Vijay Thorappadi — continue to be associated with the business. No standalone revenue, funding rounds, patents, or AI/technology capabilities are disclosed in the available data.

Novitium Pharma firmographics

Firmographics
Name
Novitium Pharma
Legal name
Novitium Pharma LLC
Website
https://novitiumpharma.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
101–250 employees
Short description
Novitium Pharma is a US-based niche generic pharmaceutical company founded in 2016, developing, manufacturing, and distributing affordable generic medications in oral suspension, tablet, and capsule forms. Acquired by ANI Pharmaceuticals in 2021, it serves pharmacists and patients across diverse therapeutic categories from its East Windsor, NJ facility.
Ownership category
akta.pro rank

Novitium Pharma industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAD
Oral Solid Dose (OSD) Generics

Keywords

  • Generic pharmaceuticals
  • Niche generic medications
  • Oral suspension formulations
  • Prescription drug manufacturing
  • US-based pharmaceutical manufacturing

Where Novitium Pharma is headquartered

Location

Headquarters

HQ city
Windsor
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Novitium Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

  1. Generic Pharmaceutical Products: Novitium generates revenue through the development, manufacturing, and distribution of niche generic pharmaceutical products. The company sells generic versions of brand medications across various dosage forms and therapeutic categories.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Novitium Pharma product offering

Product offering

Core offering

Novitium Pharma develops, manufactures, and distributes niche generic pharmaceutical products in dosage forms including oral suspensions, tablets, and capsules across various therapeutic categories. The company's products are manufactured at a state-of-the-art facility in East Windsor, New Jersey, and address formulations with limited competition in the generics market.

Product overview

Novitium Pharma is a U.S.-based pharmaceutical company specializing in development, manufacturing, and distribution of niche generic products. Founded in 2016, the company offers a portfolio of high-quality generic medications including oral suspensions (Famotidine, Sildenafil), tablets (Fluphenazine Hydrochloride), and capsules (Thiothixene). Novitium Pharma operates as part of ANI Pharmaceuticals following its acquisition and serves pharmacists and patients by providing affordable prescription options. The company's products span diverse therapeutic categories and dosage forms, all proudly manufactured in the USA at their state-of-the-art facility in East Windsor, New Jersey.

Differentiator

Problem solved

Functional benefit

Products and services

  • Famotidine for Oral Suspension, USP Generic oral suspension formulation of Famotidine manufactured and distributed by Novitium Pharma.
  • Fluphenazine Hydrochloride Tablets, USP Generic tablet formulation of Fluphenazine Hydrochloride manufactured and distributed by Novitium Pharma.
  • Sildenafil for Oral Suspension Generic oral suspension formulation of Sildenafil manufactured and distributed by Novitium Pharma.
  • Thiothixene Capsules, USP Generic capsule formulation of Thiothixene manufactured and distributed by Novitium Pharma.

Companies that use Novitium Pharma

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Novitium Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Novitium Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ANI PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2021Novitium Pharma was acquired by ANI Pharmaceuticals in 2021. This acquisition significantly enhanced ANI's R&D capabilities and scale of generics and CDMO businesses. Novitium now operates as part of ANI Pharmaceuticals, with its website indicating Novitium is now part of ANI Pharmaceuticals.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Novitium Pharma competitors and assessment

Company assessment

Direct peers

  • Amneal Pharmaceuticals: Amneal Pharmaceuticals is a major US-based generic pharmaceutical manufacturer with a similarly diverse portfolio spanning multiple dosage forms and therapeutic categories. Both serve pharmacy channels with affordable generics and share manufacturing footprint overlap.
  • Recordati Rare Diseases: Recordati Rare Diseases is identified alongside Novitium as a key Carglumic Acid competitor and operates in rare-disease and specialty pharmaceuticals. Direct overlap exists in niche/rare generic and specialty therapeutics.
  • Lannett Company: Lannett Company is a US-based generic pharmaceutical manufacturer focused on oral solid, liquid, and topical dosage forms distributed through pharmacy channels. It directly overlaps with Novitium's generic portfolio approach and distribution model.
  • Upsher-Smith Laboratories: Upsher-Smith Laboratories is a US-based generic and specialty pharmaceutical manufacturer producing tablets, capsules, and oral liquids. Its niche-focused generic strategy and US manufacturing footprint closely mirror Novitium's operating model.
  • Eton Pharmaceuticals: Eton Pharmaceuticals is a niche specialty pharmaceutical company explicitly identified alongside Novitium as a key player in the Carglumic Acid market. Both companies target underserved therapeutic niches with small, focused product portfolios and similar business models.

Broad incumbents

  • ANI Pharmaceuticals: ANI Pharmaceuticals (NASDAQ: ANIP) is the publicly-traded parent company that acquired Novitium in 2021. It operates a broader generics, specialty, and CDMO portfolio and shares overlap with Novitium across generic pharmaceuticals and contract manufacturing, making it the most directly comparable broad incumbent.
  • Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive operations in the US across tablets, capsules, and oral suspensions. It represents the broad incumbent competitive benchmark against which niche generic players like Novitium compete.
  • Sandoz (Novartis): Sandoz is a global leader in generics and biosimilars with substantial US presence across all major dosage forms. Relevant broad incumbent for benchmarking Novitium's positioning in the US generic pharmaceutical market.
  • Endo International: Endo International is a broad specialty and generic pharmaceutical manufacturer with significant US generic operations across multiple therapeutic categories. Comparable to Novitium as a larger incumbent in the US generics market.

Emerging players

  • Woodward Pharma Services: Woodward Pharma Services is a smaller US-based specialty generic manufacturer focused on niche therapeutic categories with limited competition. It shares Novitium's niche-targeting strategy and sub-scale emerging-player profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Novitium Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novitium Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Novitium Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novitium Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novitium Pharma

What does Novitium Pharma do?

Novitium Pharma develops, manufactures, and distributes niche generic pharmaceutical products in dosage forms including oral suspensions, tablets, and capsules across various therapeutic categories. The company's products are manufactured at a state-of-the-art facility in East Windsor, New Jersey, and address formulations with limited competition in the generics market.

Is Novitium Pharma a public or private company?

Novitium Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Novitium Pharma founded?

Novitium Pharma was founded in 2016. It employs 101 to 250 people.

Where is Novitium Pharma based?

Novitium Pharma is headquartered in Windsor, United States, in the North America region.

How does Novitium Pharma make money?

One revenue line is on record: generic Pharmaceutical Products.

Who are Novitium Pharma's main competitors?

Direct peers on record are Amneal Pharmaceuticals, Recordati Rare Diseases, Lannett Company, Upsher-Smith Laboratories and Eton Pharmaceuticals. Broad incumbents are ANI Pharmaceuticals, Teva Pharmaceutical Industries, Sandoz (Novartis) and Endo International. Woodward Pharma Services is listed as an emerging player.

Does Novitium Pharma have an API?

No public API is recorded for Novitium Pharma.

What industry is Novitium Pharma in?

Novitium Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial GuidanceANI Pharmaceuticals reported Q1 2026 net revenue of $237.5 million, up 20.5% year-over-year, and raised its 2026 guidance to $1,080–$1,140 million in total net revenue. The company also authorized a $100 million share repurchase program.STATBuilding a diversified biopharma company across rare disease, branded, and generics to serve patients in needANI Pharmaceuticals, a U.S.-focused biopharma company, is building a diversified portfolio across rare disease, branded, and generics. It acquired Novitium Pharma in 2021, adding R&D and manufacturing capacity, and achieved 15+ new product approvals. The company aims to transform into a leading biopharmaceutical company with significant future growth.BioSpaceANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO BusinessesANI Pharmaceuticals has completed its acquisition of Novitium Pharma, a New Jersey-based pharmaceutical company, to expand its generics and CDMO businesses. The transaction involves an $89.5 million cash payment and the issuance of equity, along with a new capital structure including a $300 million Term Loan-B. This move positions ANI with enhanced R&D capabilities and a pipeline focused on niche opportunities, including 505(b)(2) candidates in oncology and hypertension.PR NewswireLannett To Launch Levorphanol TabletsLannett Company, Inc. announced it will soon launch Levorphanol Tablets 2 mg under an exclusive U.S. distribution agreement with Novitium Pharma. Novitium received FDA approval for the product earlier this month, and Lannett will provide sales, marketing, and distribution support in exchange for a share of profits. Total U.S. sales for Levorphanol Tablets 2 mg were approximately $60.9 million for the 12 months ended May 2020, according to IQVIA, though actual generic market values are expected to be lower.PR NewswireEndo Announces Approval of First Generic Orfadin® in U.S.Endo International plc announced that Novitium Pharma, LLC, a partner of its subsidiary Endo Ventures Limited, has received approval from the U.S. Food and Drug Administration for a generic version of Orfadin (nitisinone capsules). This approval represents the first and only bioequivalent option to Orfadin, expected to be distributed through specialty pharmacies starting this month. Nitisinone capsules are indicated for treating hereditary tyrosinemia type 1, a rare metabolic disorder affecting at least 150 patients in the United States.GlobeNewswireNovitium Pharma Launches Generic Revatio® for Oral Suspension, 10mg/mLNovitium Pharma received FDA clearance for its generic Sildenafil oral suspension, 10mg/mL, a product currently on the FDA drug shortages list. The generic holds a Competitive Generic Therapy Designation, marking Novitium's third such ANDA and seventh overall in 2019. The original Revatio had a market value of about $200 million for the 12 months ending March 2019.GlobeNewswireNovitium Pharma Launches Prazosin Hydrochloride Capsules USPNovitium Pharma received FDA approval for its ANDA of Prazosin Hydrochloride Capsules USP 1, 2, and 5 mg and began commercialization. The product is a therapeutic equivalent to Pfizer's Minipress, with U.S. sales of the three strengths reaching about $65 million in the year ended June 2018.